Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Genmab ( (GMAB) ).
Genmab A/S, the Copenhagen-based biotechnology group specializing in antibody medicines for oncology and other serious illnesses, has built a portfolio that includes bispecific antibodies, antibody-drug conjugates and immune-modulating antibodies. The company’s science underpins eight approved antibody drugs and supports a late-stage clinical pipeline of both partnered and wholly owned programs targeting transformative treatments.
On February 17, 2026, Genmab announced the launch of a share buy-back program to meet obligations under its Restricted Stock Unit scheme. Beginning February 18 and running no later than March 31, 2026, the company may repurchase up to 342,130 shares for a maximum of 725 million DKK via Danske Bank under a non-discretionary mandate, a move that modestly increases potential capital returns while managing dilution and adds to the 2,615,851 treasury shares already held.
The buy-back will be executed on Nasdaq Copenhagen and other multilateral trading facilities in line with EU “Safe Harbour” rules governing price and volume, including daily caps tied to recent trading volumes. Genmab retains the right to suspend or terminate the program and will provide weekly disclosures on repurchases, offering investors transparency on execution and the pace of treasury share accumulation supporting its equity compensation strategy.
The most recent analyst rating on (GMAB) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Headquartered in Copenhagen with operations across North America, Europe and Asia Pacific, it has spent over 25 years advancing bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies and other next-generation modalities, powering eight approved antibody therapies and a strong late-stage pipeline.
Average Trading Volume: 1,609,924
Technical Sentiment Signal: Buy
Current Market Cap: $18.6B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.